文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

低剂量氯胺酮治疗急性疼痛:一项叙述性综述

Low-dose ketamine for acute pain: A narrative review.
PubMed 文献 · Am J Emerg Med · 2024-09-16
一句话结论低剂量氯胺酮用于急性疼痛安全有效,可替代阿片类药物或作为辅助减少阿片用量,剂量<0.5 mg/kg未伴显著副作用。

本文为一项范围叙述性综述,检索PubMed截至2024年1月30日的英文前瞻性和回顾性临床研究,最终纳入64项研究(院前21项含4项RCT,急诊43项含28项RCT)。研究提示低剂量氯胺酮单用时非劣于阿片类药物,作为阿片辅助时可产生阿片节省效应,剂量<0.5 mg/kg未伴显著副作用。低剂量氯胺酮有肌内、静脉、鼻内等多种剂型,适用于院前和急诊环境。作者认为其是急性疼痛治疗的安全有效选择,可替代或联合阿片类药物。

要点

  • 低剂量氯胺酮单用时非劣于阿片类药物,可作为急性疼痛的替代治疗。
  • 作为阿片类药物辅助时,低剂量氯胺酮可产生阿片节省效应,减少阿片暴露。
  • 氯胺酮剂量<0.5 mg/kg未伴显著副作用。
  • 低剂量氯胺酮有肌内、静脉、鼻内等剂型,适用于院前和急诊环境。
  • 纳入64项研究:院前21项(含4项RCT),急诊43项(含28项RCT)。

适用人群与场景

  • 院前和急诊科环境中急性疼痛患者;综述未限制患者人群或给药方式。

处置流程与药物剂量

  • 低剂量氯胺酮可单用替代阿片类药物,或与阿片类药物联用以减少阿片暴露;可用剂型包括肌内、静脉和鼻内给药。
  • 氯胺酮剂量<0.5 mg/kg未伴显著副作用。

研究设计与关键结果

  • 范围叙述性综述,检索PubMed截至2024年1月30日的英文前瞻性和回顾性临床及观察性研究,采用PRISMA-ScR清单。
  • 初检249篇,摘要审阅排除178篇,71篇进一步全文审阅,排除22篇,43篇符合初始纳入标准,滚雪球法补充22篇,最终纳入64项研究。
  • 院前研究21项,其中4项为随机对照试验(RCT);急诊研究43项,其中28项为RCT。
  • 总体研究提示低剂量氯胺酮单用时非劣于阿片类药物;作为阿片类药物辅助时可产生阿片节省效应;剂量<0.5 mg/kg未伴显著副作用。

证据类型、等级与局限

  • 证据类型:范围叙述性综述,纳入前瞻性和回顾性临床及观察性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为低剂量氯胺酮是急性疼痛治疗的安全有效选择,可替代阿片类药物或与阿片类药物联用以减少阿片暴露。
  • 作者认为低剂量氯胺酮的多种剂型(肌内、静脉、鼻内)使其在院前和急诊环境中均为有效的急性疼痛治疗选择。
  • 作者认为低剂量氯胺酮在不断演变的急性疼痛管理中作为急诊治疗具有前景。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: Acute pain management is a critical component of prehospital and emergency medical care. Opioids are effective; however, the risks and side-effects of opioids have led providers to use low-dose ketamine (LDK) for safe and effective treatment of acute pain.

METHODS: We conducted a scoping narrative review to explore the efficacy of LDK for the treatment of acute pain in the prehospital setting and emergency department (ED) setting. The prehospital review includes studies evaluating the use of LDK in both civilian and military settings. We utilized PubMed to identify prospective and retrospective clinical studies related to this topic. We limited study inclusion to quality prospective and retrospective clinical and observational studies published in the English language prior to January 30, 2024. We did not limit study inclusion based on patient population or mode of administration. We utilized the PRISMA-ScR checklist to conduct this review.

RESULTS: Using our methodology, we found 249 publications responsive to our search strategy. Of these, 178 publications were clearly outside inclusion criteria based on abstract review. Seventy-one studies were sought for retrieval and more detailed review. Of these, 22 records were excluded after review and 43 met initial inclusion criteria. An additional 22 studies were found via snowballing. In total, 64 studies met inclusion criteria for this analysis. 21 studies related to the treatment of acute pain in the prehospital setting, four of which were randomized clinical trials (RCTs). Forty-three studies evaluate the treatment of acute pain in the ED. This included 28 RCTs. Taken together, the studies suggest that LDK is non-inferior to opioids when used alone. When used as an adjunct to opioid therapy, LDK can provide an opioid-sparing effect. Ketamine doses <0.5 mg/kg were not associated with significant side effects.

CONCLUSIONS: LDK is a safe and effective option for acute pain treatment. It can be used as an alternative therapy to opioids or used in conjunction with them to reduce opioid exposure through its opioid-sparing effect. Importantly, LDK is available in a variety of formulations including intramuscular, intravenous, and intranasal, making it an effective acute pain treatment option in both the prehospital and ED settings. LDK holds promise as an emergency treatment in the evolving landscape of acute pain management.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Fuller RG, Kikla EM, Fawcett APW, et al. Low-dose ketamine for acute pain: A narrative review. Am J Emerg Med. 2024. PMID: 39326173. doi:10.1016/j.ajem.2024.09.033

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。